The HIV-CAUSAL Collaboration a Background. Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiretroviral regimens. However, these guidelines are based on limited evidence from randomized clinical trials and clinical experience.
However, these guidelines are based on limited evidence as these regimens have not been extensively examined in previous studies. In particular, the guidelines are largely based on clinical experience and the results of a single randomized trial, the CAS-TLE study [6, 7] . This trial compared ritonavir-boosted atazanavir with ritonavir-boosted lopinavir in combination with tenofovir and emtricitabine and found that the proportions with HIV RNA <50 copies/mL and the mean increases in CD4 cell count were similar between arms at the end of follow-up. However, follow-up was limited to 48 and 96 weeks, clinical outcomes such as death and AIDS-defining illness were not assessed, and estimates for AIDS-free individuals (who are an increasing proportion of initiators of antiretroviral therapy) were not able to be estimated.
A more recent trial, the NORTHIV study, compared ritonavir-boosted atazanavir vs ritonavir-boosted lopinavir in combination with 2 NRTIs of the physician's choice. The estimates for immunologic and virologic outcomes were similar to those of the CASTLE study [8] . Again, follow-up was limited (48 and 144 weeks), no clinical outcomes were evaluated, and estimates were not reported for AIDS-free individuals.
Here we aim to complement the randomized trials by providing new evidence on clinical outcomes. We examine deaths and AIDS-defining illnesses among AIDS-free patients who start a first-line regimen consisting of either ritonavir-boosted lopinavir or ritonavir-boosted atazanavir with an NRTI backbone in a large collaboration of prospective cohort studies from the United States and Europe. We also study short-term immunologic and virologic outcomes for comparison with the CASTLE and NORTHIV studies.
METHODS

Study Population
The HIV-CAUSAL Collaboration has been described elsewhere [9] . In brief, the collaboration includes several prospective cohort studies from 6 European countries and the United States: UK CHIC (United Kingdom), ATHENA (the Netherlands), FHDH-ANRS CO4 (France), Aquitaine (France), SHCS (Switzerland), PISCIS (Spain), CoRIS (Spain), VACS-VC (United States veterans), AMACS (Greece), UK Register of HIV Seroconverters (United Kingdom), ANRS PRIMO (France), and GEMES (Spain). All cohorts included in the HIV-CAUSAL Collaboration were assembled prospectively and are based on data collected for clinical purposes within national healthcare systems with universal access to care. Each cohort in the collaboration collects data on all CD4 cell counts, HIV RNA levels, treatment initiations, AIDS-defining illnesses, and deaths.
For each individual, follow-up started at the initiation of an eligible antiretroviral regimen (baseline). Our analysis was restricted to HIV-infected individuals who met the following eligibility criteria at baseline dates between 2004 and 2013; age ≥18 years, previously antiretroviral therapy naive, no history of an AIDS-defining illness [10] , no pregnancy (when information was available), and CD4 cell count and HIV RNA measurements within 6 months prior to baseline. For the analysis of clinical outcomes, follow-up ended at the occurrence of the outcome, 12 months after the most recent laboratory measurement (ie, we considered an individual to be lost to followup if and when he/she had no new CD4 or RNA measurements for 12 months), pregnancy (if known), or the cohort-specific administrative end of follow-up (ranging from September 2010 to March 2013), whichever occurred first. For the analysis of immunologic and virologic outcomes, follow-up ended on average at 12 months after baseline.
Outcomes
We considered clinical, immunologic, and virologic outcomes. The clinical outcomes of interest were death from any cause and clinical AIDS-defining illness [10] or death. Dates of death were identified using a combination of national and local mortality registries and clinical records as described elsewhere [9] , and AIDS-defining illnesses were ascertained by the treating physicians.
The immunologic outcome of interest was the 12-month change in CD4 cell count after baseline. If CD4 cell count was not measured exactly 12 months after baseline, we used the closest measurement within 2 months. Similarly, the virologic outcome of interest was virologic failure defined as HIV RNA >50 copies/mL at 12 ± 2 months.
Antiretroviral Regimens
We considered 2 types of first-line regimens: lopinavir and atazanavir regimens. The analysis was restricted to individuals who started ritonavir, an NRTI backbone, and either lopinavir or atazanavir at baseline. Individuals were excluded if they started an ineligible drug (ie, an NNRTI, an integrase inhibitor, a fusion inhibitor, or a PI other than ritonavir, lopinavir, or atazanavir) or both lopinavir and atazanavir at baseline.
Statistical Methods
We fit pooled logistic models to estimate the hazard ratio of each clinical outcome for atazanavir vs lopinavir regimens. Both models included a regimen indicator (1: atazanavir, 0: lopinavir), cohort, month of follow-up (modeled as a restricted cubic spline with 4 knots at 1, 6, 24, and 60 months), and the following baseline covariates: sex, age (<35, 35-49, ≥50 years), race (white, black, other, or unknown), geographic origin (Western countries, sub-Saharan Africa, other, or unknown), mode of HIV acquisition (heterosexual, homosexual/bisexual, injection drug use, other/unknown), CD4 cell count (<200, 200-299, 300-399, 400-499, ≥500 cells/µL), HIV RNA (<10 000, 10 000-100 000, >100 000 copies/mL), calendar year (2004-2007, ≥2008) , and time since HIV diagnosis (<1 year, 1-4 years, ≥5 years, or unknown). For the immunologic outcome, we fit a linear regression model with the same covariates to estimate the 12-month change in CD4 cell count for atazanavir vs lopinavir regimens among those with measurements at 12 ± 2 months. For the virologic outcome, we fit a modified Poisson regression model [11] with the same covariates to estimate the risk ratio of virologic failure at 12 months for atazanavir vs lopinavir regimens among those with measurements at 12 ± 2 months.
Under the assumption that we measured and successfully adjusted for all confounders, the estimated coefficient for the regimen indicator in the adjusted models can be interpreted as the 'intention-to-treat' effect that would have been estimated from an open-label randomized trial with similar adherence and follow-up. Because we defined the clinical regimens of interest in terms of the first-line regimen only, it was unnecessary to adjust for joint determinants of switching and death. The Supplementary Appendix Table shows estimates from unadjusted models.
For the 2 clinical outcomes, we also estimated absolute risks by fitting adjusted models such as the one described above that also included product ("interaction") terms between the regimen indicator and month of follow-up with spline terms. The models' predicted values were then used to estimate the 5-year survival and 5-year AIDS-free survival curves from baseline.
For death, we also estimated the hazard ratio in subsets defined by baseline calendar year, sex, age, mode of HIV acquisition, baseline CD4 cell count, and baseline HIV RNA. For AIDS-defining illness or death, we also estimated the hazard ratio in subsets defined by NRTI backbone. Because of limited numbers of deaths, we were not able to look at subsets defined by NRTI backbone for our death-only outcome.
Sensitivity Analyses
Because the lower limit of detection was unknown in <5% of observations with HIV RNA between 50 and 400 copies/mL, we conducted a sensitivity analysis in which we defined virologic failure as HIV RNA >400 copies/mL.
In another sensitivity analysis, we allowed a 6-month grace period for individuals to complete one of the regimens of interest as opposed to requiring individuals to start all of the drugs in their regimen simultaneously. Individuals were artificially censored if and when they started an ineligible drug before completing a regimen or at 6 months from baseline if their regimen was not yet complete. As previously described, to adjust for potential selection bias due to the artificial censoring, we estimated unstabilized inverse probability weights [12] via pooled logistic models for artificial censoring that included the time-fixed covariates and time-varying CD4 cell count (restricted cubic spline with 5 knots at 10, 200, 350, 500, and 1000 cells/µL), HIV RNA (<10 000, 10 000-100 000, >100 000 copies/mL), AIDS-defining illness (when the outcome was death alone), and time since last laboratory measurement (0, 1-2, 3-4, 5-6, ≥7 months). Note that inverse-probability weighting was not necessary in our main analysis, as treatment was determined at baseline.
Several other sensitivity analyses were also performed. For all 4 outcomes, we used continuous as opposed to categorical baseline covariates, weighted by the inverse probability of remaining uncensored due to infrequent laboratory measurements, and investigated the effect of including chronic hepatitis C infection [13] as a baseline covariate. For the immunologic and virologic outcomes, we also weighted by the inverse probability of remaining alive and having a measurement at 12 ± 2 months after baseline as a form of competing risk analysis.
All 95% confidence intervals (CIs) were estimated via a nonparametric bootstrap with 500 samples. All analyses were conducted with SAS software version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
The dataset included 10 969 individuals, of whom 6668 followed a lopinavir regimen and 4301 followed an atazanavir regimen. Table 1 shows the characteristics of the study population by regimen type at baseline. Women, individuals aged <35 years at baseline, those from non-Western countries, those with the lowest baseline CD4 cell counts, those with the highest baseline HIV RNA levels, and those starting treatment before 2008 were more likely to initiate lopinavir than atazanavir.
In the mortality analysis, the median follow-up time was 40 (interquartile range [IQR], 20-61) months for the lopinavir regimens and 27 (IQR, 14-45) months for the atazanavir regimens. In the AIDS-defining illness or death analysis, the median follow-up time was 37 (IQR, 18-60) months for the lopinavir regimens and 26 (IQR, 13-44) months for the atazanavir regimens. There were 3322 individuals lost to follow-up in the death analysis, of whom 2366 followed a lopinavir regimen and 956 followed an atazanavir regimen. In the AIDS or death analysis, 3228 were lost to follow-up, of whom 2290 followed a lopinavir regimen and 938 followed an atazanavir regimen.
As shown in Table 2 , 213 and 83 individuals died and 457 and 157 individuals developed an AIDS-defining illness or died among those initiating a lopinavir and an atazanavir regimen, respectively. Compared with lopinavir, the hazard ratio for atazanavir was 0.70 (95% CI, .53-.91) for death and 0.67 (95% CI, .55-.82) for AIDS or death. Table 2 also shows the 12-month adjusted mean change in CD4 cell count and the number with virologic failure at 12 ± 2 months. Compared with lopinavir, the estimated mean change in CD4 cell count for atazanavir was 8.15 (95% CI,
Among those initiating lopinavir and atazanavir regimens, 26% and 24%, respectively, had HIV RNA >50 copies/mL at 12 months. Compared with lopinavir, the risk ratio of virologic failure for atazanavir was 0.91 (95% CI, .84-.99). Figure 1 plots the estimated 5-year survival and 5-year AIDSfree survival. The survival was 96.1% (95% CI, 95.5%-96.7%) for the lopinavir regimens and 97.1% (95% CI, 96.5%-97.8%) for the atazanavir regimens. The 5-year survival difference was 1.0% (95% CI, .1%-1.9%). The AIDS-free survival proportion was 92.3% (95% CI, 91.5%-93.1%) for the lopinavir regimens and 94.4% (95% CI, 93.5%-95.4%) for the atazanavir regimens. The 5-year AIDS-free survival difference was 2.2% (95% CI, .9%-3.4%).
In subset analyses, the mortality hazard ratio was 0.45 (95% CI, .26-.77) when we restricted to baseline calendar years 2008 and beyond; 0.65 (95% CI, .49-.88) when we restricted to men, 0.59 (95% CI, .41-.87) when we restricted to individuals aged <50 years; 0.69 (95% CI, .52-.91) when we restricted to noninjection drug users; 0.62 (95% CI, .46-.84) when we restricted to those with baseline CD4 cell counts <350 cells/µL; 0.57 (95% CI, .37-.88) when we restricted to those with baseline viral loads >100 000 copies/mL; and 0.72 (95% CI, .54-.96) when we restricted to those from Western countries. Table 3 shows the number and percentage of individuals taking recommended NRTI backbones by regimen type. Backbones consisting of abacavir/lamivudine and tenofovir/ emtricitabine were more frequently used with atazanavir, whereas backbones of zidovudine/lamivudine and tenofovir/lamivudine were more frequently used with lopinavir. Table 3 also shows the hazard ratio for AIDS or death by NRTI backbone. Compared with lopinavir, the hazard ratio for atazanavir ranged from 0.50 (95% CI, .38-.65) for tenofovir/emtricitabine to 1.12 (95% CI, .48-2.60) for zidovudine/lamivudine.
None of the sensitivity analyses yielded appreciably different results (data not shown), with the exception of the alternative definition of virologic failure. When we defined virologic failure as HIV RNA >400 copies/mL, 14% and 10% of those initiating lopinavir and atazanavir, respectively, had HIV RNA >400 copies/mL at 12 months. The risk ratio of virologic failure (HIV RNA >400 copies/mL) was 0.79 (95% CI, .69-.90) for atazanavir vs lopinavir (see Supplementary Appendix Table) .
DISCUSSION
The clinical effectiveness of ritonavir-boosted atazanavir vs ritonavir-boosted lopinavir has not been directly studied in randomized trials, which have focused on short-term immunologic and virologic outcomes. Our study compared atazanavir vs lopinavir regimens with respect to clinical outcomes among antiretroviral-naive, AIDS-free individuals in Europe and the United States. We estimated a 30% mortality reduction and a 33% reduction in a combined endpoint of death and AIDSdefining illness for atazanavir vs lopinavir. We also found that atazanavir had a beneficial but modest effect on immunologic and virologic outcomes.
Unlike previous observational studies [14, 15] , we designed our observational analysis to emulate the intention-to-treat analysis of a randomized clinical trial in which antiretroviralnaive, AIDS-free adults are randomized to receive either ritonavir-boosted lopinavir or ritonavir-boosted atazanavir with an NRTI backbone. Our estimates are based on less restrictive criteria, and therefore are potentially more relevant to the general population of HIV-infected patients than those of the CASTLE Table 2 Table 2 footnotes.
[ 6, 7] and NORTHIV studies [8] . When we more closely emulated the design and inclusion criteria of the CASTLE study (ie, baseline HIV RNA ≥5000 copies/mL, and an NRTI backbone of tenofovir and emtricitabine), we estimated a risk ratio of virologic failure of 1.00 (95% CI, .89-1.13), similar to 1.06 (95% CI, .73-1.53) from our meta-analysis of the 2 trials. Our study, however, may still differ from the CASTLE and NORTH IV studies in several ways. In the CASTLE Study, both arms had a backbone of tenofovir and emtricitabine. In the NORTHIV study, as in our study, the prescribing physician could select the backbone. We conducted analyses restricted to 4 recommended backbones for the outcome AIDS-defining illness or death. Our estimates differed by NRTI backbone. Although we found little difference between lopinavir and atazanavir for those on the NRTI backbones abacavir/lamivudine, zidovudine/lamivudine, and tenofovir/ lamivudine, our results may suggest an interaction between lopinavir and tenofovir/emtricitabine that results in lower regimen potency. As this is the most commonly used NRTI backbone, this interaction merits further investigation.
In the CASTLE and NORTHIV studies, individuals received 400 mg/100 mg of lopinavir/ritonavir twice daily. We do not know whether individuals on lopinavir regimens in our study were taking their medication once or twice daily. Although once-daily regimens are generally associated with better adherence, this is unlikely to be a source of bias as both schedules performed similarly in randomized clinical trials [16] [17] [18] .
As with all observational estimates, ours rely on the untestable assumption that we have successfully measured and adjusted for all confounders. In this analysis, we measured and adjusted for sex, age, race, geographic origin, mode of HIV acquisition, CD4 cell count, HIV RNA, calendar year, and years since HIV diagnosis. If further adjustment is necessary to account for confounding factors responsible for large prognostic differences between patients initiating lopinavir vs atazanavir, the assumption would not hold.
One of these confounding factors might be adherence if lopinavir was more often prescribed to individuals whose future adherence was questionable (eg, because of markers of poor health such as hepatic diseases) even in the absence of a clinical indication for switching or treatment discontinuation. However, we measured and adjusted for several proxies for adherence, including HIV RNA, calendar year, intravenous drug use, years since HIV diagnosis, and time since last laboratory measurement.
Another potential confounding factor is concomitant medication use. For example, ritonavir-boosted atazanavir is not recommended for use with antacids and other drugs that raise gastric pH [2] , whereas ritonavir-boosted lopinavir may lead to increased statin use because of unfavorable lipid changes and increased risk of myocardial infarction [19] [20] [21] . Although we could not adjust for non-antiretroviral drug use, the magnitude of the reported associations makes it unlikely that our immunologic and virologic estimates can be fully explained by use of antacids, statins, or other drugs.
In summary, our findings extend those of randomized trials from immunologic and virologic outcomes to clinical outcomes. Although we provide new evidence upon which the next set of guidelines can be based, our findings do not support changes to the current guidelines. Future studies need to consider the effects of lopinavir and atazanavir on other clinical outcomes including non-AIDS-defining illnesses, when paired with specific backbones, particularly tenofovir/emtricitabine, and over longer periods.
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